Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002153 · ClinicalTrials.gov registry record · Phase 1
Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders
A Phase 1 study, sponsored by DEKK-TEC.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00002153 is a Phase 1 study that has completed, run by DEKK-TEC. The registered enrollment target is 25 participants.
The verdict
NCT00002153, a Phase 1 study, has completed, sponsored by DEKK-TEC.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
To evaluate topical A-007 in patients with advanced malignancies including Kaposi's sarcoma and lymphoproliferative disorders.
Interventions
- DRUG A-007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002153
The ClinicalTrials.gov registry entry for NCT00002153 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DEKK-TEC, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which A-007 is the first listed.
NCT00002153 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002153 about?
NCT00002153 is a clinical study titled "Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders". To evaluate topical A-007 in patients with advanced malignancies including Kaposi's sarcoma and lymphoproliferative disorders.
What is the current status of trial NCT00002153?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants.
What interventions are being tested in trial NCT00002153?
The interventions under investigation include: A-007 (DRUG).
Who is sponsoring clinical trial NCT00002153?
This trial is sponsored by DEKK-TEC, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.